| Literature DB >> 24901000 |
Rodrigo Luiz Fabri1, Danielle Maria de Oliveira Aragão1, Jônatas Rodrigues Florêncio1, Nícolas de Castro Campos Pinto1, Ana Carolina Alves Mattos2, Paulo Marcos Zech Coelho2, Maria Christina Marques Nogueira Castañon3, Eveline Gomes Vasconcelos4, Priscila de Faria Pinto4, Elita Scio1.
Abstract
The aims of this work were to evaluate the in vitro and in vivo schistosomicidal properties of the methanolic extract of the aerial parts of Mitracarpus frigidus (MFM) and to determine its HPLC profile. For the in vitro experiment, four pairs of adult worms, obtained from infected mice, were exposed to different concentrations of MFM (100 to 400 μg/mL) for 24 and 48 h and analyzed under an inverted microscope. For the in vivo experiment, mice were inoculated with cercariae and, 20 days after infection, MFM (100 and 300 mg/kg) was administered orally for the following 25 days. Mice were euthanized after 60 days. MFM showed in vitro schistosomicidal activity, exhibiting the opening of the gynaecophoral canal of some male schistosomes, the presence of contorted muscles, vesicles, and the darkening of the paired worms skin. In vivo experiments showed that MFM treatments significantly reduced total worm count, as praziquantel, showing a decrease in liver and spleen weight. Also, a significant reduction in granuloma density was observed. MFM treatment did not cause alterations in the liver function of either infected or noninfected mice. The HPLC chromatogram profile showed the presence of kaempferol-O-rutinoside, rutin, kaempferol, psychorubrin, and ursolic acid.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24901000 PMCID: PMC4034476 DOI: 10.1155/2014/941318
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1In vitro schistosomicidal activity of Mitracarpus frigidus methanolic extract (MFM) at 100 μg/mL concentration after 24 hours of incubation. (a) Paired worms incubated in culture medium—the arrow shows pairs united in gynecophoral canal; (b) female worm incubated only with culture medium, showing eggs in the first stage of growth (arrow); (c) male worm showing fully open gynecophoral canal (arrow); (d) female worm showing contorted muscles; (e) and (f) presence of vesicles in female worm tegument sections.
Effects of Mitracarpus frigidus methanolic (MFM) extract treatment on body weight, relative organ weights, and granuloma formation, after 60 days of infection.
| Non-infected groups | Infected groups | |||||||
|---|---|---|---|---|---|---|---|---|
| Group A | Group B | Group C | Group D | Group E | Group F | Group G | Group H | |
| Negative control | Praziquantel | MFM | MFM | Negative control | Praziquantel | MFM | MFM | |
| 200 mg/kg | 100 mg/kg | 300 mg/kg | 200 mg/kg | 100 mg/kg | 300 mg/kg | |||
| Body weight (g) | 26.5 ± 0.5 | 24.5 ± 0.7 | 24.8 ± 0.9 | 25.3 ± 0.6 | 28.0 ± 0.5 | 27.9 ± 0.5 | 26.5 ± 0.5 | 24.5 ± 0.7 |
| Relative liver weights | 4.9 ± 0.2 | 5.4 ± 0.2 | 5.4 ± 0.1 | 5.4 ± 0.2 | 12.8 ± 0.7 | 12.0 ± 0.4 | 4.9 ± 0.2 | 5.4 ± 0.2 |
| Relative spleen weights | 0.3 ± 0.04 | 0.3 ± 0.04 | 0.4 ± 0.03 | 0.5 ± 0.09 | 3.4 ± 0.2 | 2.8 ± 0.3 | 0.3 ± 0.04 | 0.3 ± 0.04 |
| Number of granulomas | — | — | — | — | 62.2 ± 1.6 | 45.1 ± 3.1a | — | — |
| Mean granuloma diameter ( | — | — | — | — | 7.4 ± 0.3 | 8.8 ± 0.1a | — | — |
The values shown are mean ± SEM (n = 10). aStatistically different from the infected, negative control group (E) (ANOVA followed by Bonferroni, P < 0.05).
Figure 2Effects of Mitracarpus frigidus methanolic extract on hepatic granuloma. At 60 days of infection, the hepatic tissues were collected and used for morphological study of the granulomatous area. All granulomas containing a central viable egg were measured and photographed. In (a) general aspects of the hepatic granulomas obtained from infected and untreated animals; (b) the infiltrate around the granuloma in treated animals with a single dose (200 mg/kg) of praziquantel is shown. In ((c), 100 mg/Kg) and ((d), 300 mg/kg) the granulomas from infected and treated animals after 20 days with different doses of the M. frigidus extract, showing that there are no changes in their structure and granulomatous infiltrate.
Results obtained in mice experimentally infected with 50 ± 10 cercariae of Schistosoma mansoni (LE strain) treated with Mitracarpus frigidus, orally, after 60 days of infection.
| Groups | Worm distribution | |||||
|---|---|---|---|---|---|---|
| Liver | Mesentery | Total | ||||
| Means of worms | Reductionc
| Means of worms | Reductionc
| Global means | Global reductionc
| |
| Negative control | 4.6 ± 1.0 | — | 19.2 ± 1.4 | — | 23.0 ± 1.0 | — |
| Praziquantel | 2.4 ± 0.7a | 48 | 9.4 ± 1.7a | 51 | 11.8 ± 2.0a | 49 |
| MFM | 0.4 ± 0.4a,b | 91 | 6.8 ± 1.6a | 65 | 7.2 ± 1.9a | 69 |
| MFM | 1.6 ± 0.8a | 65 | 8.0 ± 1.5a | 58 | 9.6 ± 1.7a | 58 |
The values shown are mean ± SEM (n = 8). aStatistically different from the negative control group. bStatistically different from the positive control group (praziquantel) (ANOVA followed by the Bonferroni test, P < 0.05). cPercentage reduction (%) = {1 − (mean of worms in the negative control group/mean of worms in the groups treated)} × 100.
Effects of Mitracarpus frigidus methanolic extract (MFM) treatment on the biochemical and hematological parameters, after 60 days of infection.
| Noninfected groups | Infected groups | |||||||
|---|---|---|---|---|---|---|---|---|
| Group A | Group B | Group C | Group D | Group E | Group F | Group G | Group H | |
| Negative control | Praziquantel | MFM | MFM | Negative control | Praziquantel | MFM | MFM | |
| 200 mg/kg | 100 mg/kg | 300 mg/kg | 200 mg/kg | 100 mg/kg | 300 mg/kg | |||
| Total protein (g/dL) | 13.2 ± 0.2 | 10.6 ± 0.3 | 12.5 ± 0.5 | 11.4 ± 0.5 | 5.1 ± 0.2 | 4.8 ± 0.2 | 5.7 ± 0.2 | 5.4 ± 0.2 |
| Albumin (g/dL) | 4.4 ± 0.4 | 3.0 ± 0.2a | 2.3 ± 0.1a,b | 1.8 ± 0.1a,b | 2.8 ± 0.2 | 2.7 ± 0.2 | 2.7 ± 0.2 | 3.1 ± 0.2 |
| Globulin (g/dL) | 7.9 ± 1.4 | 7.6 ± 0.5 | 10.2 ± 0.6a,b | 9.8 ± 0.4a,b | 2.3 ± 0.2 | 2.0 ± 0.3 | 3.0 ± 0.3c,d | 2.4 ± 0.3 |
| A/G | 0.5 ± 0.1 | 0.4 ± 0.05 | 0.2 ± 0.02 | 0.2 ± 0.02 | 1.3 ± 0.3 | 2.1 ± 0.6c | 1.0 ± 0.1d | 1.6 ± 0.3 |
| ALP (U/L) | 17.5 ± 1.5 | 22.7 ± 2.1 | 12.2 ± 1.4b | 7.7 ± 1.9a,b | 55.1 ± 5.0 | 38.7 ± 3.2c | 38.7 ± 3.9c | 41.7 ± 3.4c |
| AST (U/L) | 10.9 ± 1.3 | 18.6 ± 4.3a | 8.5 ± 1.4b | 13.2 ± 3.1 | 44.6 ± 3.8 | 21.0 ± 3.5c | 26.8 ± 1.9c | 32.3 ± 3.0c,d |
| ALT (U/L) | 17.9 ± 2.8 | 9.3 ± 1.6a | 11.6 ± 2.7 | 6.3 ± 1.0a | 33.3 ± 2.3 | 29.8 ± 3.1 | 4.2 ± 0.4c,d | 14.6 ± 3.5c,d |
| Total leukocytes (103/ | 5.1 ± 0.4 | 4.3 ± 0.4 | 4.8 ± 0.4 | 5.0 ± 0.4 | 8.4 ± 0.6 | 5.6 ± 0.7c | 5.7 ± 0.4c | 5.2 ± 0.4c |
| Basophil (%) | 1.0 ± 0 | 1.0 ± 0 | 1.0 ± 0 | 1.0 ± 0 | 1.0 ± 0 | 1.1 ± 0.1 | 1.2 ± 0.1 | 1.2 ± 0.1 |
| Eosinophil (%) | 2.1 ± 0.4 | 2.3 ± 0.2 | 1.9 ± 0.1 | 2.1 ± 0.1 | 20.4 ± 1.2 | 11.2 ± 1.3c | 5.1 ± 1.0c,d | 6.5 ± 1.0c,d |
| Monocyte (%) | 9.4 ± 0.5 | 7.4 ± 0.7 | 5.4 ± 0.7a | 5.2 ± 1.2a | 19.6 ± 2.2 | 10.3 ± 1.3c | 4.6 ± 1.0c,d | 9.1 ± 1.4c |
| Neutrophil (%) | 43.3 ± 3.5 | 53.6 ± 2.5a | 49.0 ± 1.4 | 49.7 ± 2.3 | 39.8 ± 2.6 | 59.4 ± 2.3c | 65.8 ± 2.0c | 65.4 ± 1.4c |
| Lymphocyte (%) | 42.4 ± 2.6 | 34.8 ± 2.5a | 45.8 ± 2.7b | 47.2 ± 2.0b | 17.4 ± 2.5 | 13.9 ± 1.2 | 20.5 ± 1.5d | 16.9 ± 1.3 |
The values shown are mean ± SEM (n = 10). aStatistically different from the noninfected, negative control Group A. bStatistically different from the noninfected, positive control Group B. cStatistically different from the infected, negative control Group E. dStatistically different from the infected, positive control Group F (ANOVA followed by the Bonferroni test, P < 0.05).
Figure 3HPLC chromatogram of Mitracarpus frigidus methanolic extract (MFM). The analysis was performed using a linear gradient of a binary solvent system A (water pH adjusted to 4.0 with H3PO4) : B (acetonitrile). The elution conditions applied were 0–20 min, 5–80% B and 20–30 min, 80–95% B. It was run at a flow rate of 1 mL/min over 30 minutes, with an injection volume (“loop”) of 20 μL and UV detection was at 230 nm.